AbbVie Submits Regulatory Application to EMA for Subcutaneous SKYRIZI in Moderately to Severely Active Crohn's Disease

AbbVie has submitted an application to the European Medicines Agency (EMA) for the approval of SKYRIZI (risankizumab) for subcutaneous induction in adult patients with moderately to severely active Crohn's disease. This submission is supported by data from the Phase 3 pivotal AFFIRM study.